Arena’s etrasimod meets primary and secondary endpoints in ulcerative colitis trial
Patients receiving the 2 mg dose of etrasimod achieved statistically significant improvements versus placebo in the primary, all secondary, and clinical remission endpoints. Relative to placebo, there was